Darya-Varia Laboratoria Tbk PT operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Darya-Varia Laboratoria Tbk PT with three other
pharmaceutical manufacturers in Asia:
Shanghai Fudan Forward S&T Co Ltd
sales of 735.73 million Chinese Renmimbi [US$105.84 million]
of which 64%
Marksans Pharma Limited
(7.67 billion Indian Rupees [US$106.10 million]
of which 100%
was Bulk Drugs Division), and
Beijing Science Sun Pharmaceutical Co Ltd
based in China
(749.99 million Chinese Renmimbi [US$107.89 million]
of which 100%
was Phamaceutical Manufacturing Industry).
During the year ended December of 2017, sales at
Darya-Varia Laboratoria Tbk PT were 1.58 trillion Indonesian Rupiahs (US$106.51 million).
increase of 8.6%
versus 2016, when the company's sales were 1.45 trillion Indonesian Rupiahs.
This was the fifth consecutive year of sales increases at Darya-Varia Laboratoria Tbk PT
(and since 2012, sales have increased a total of 45%).
Sales of Consumer Health saw an increase
14.3% in 2017, from
652.63 billion Indonesian Rupiahs to 745.92 billion Indonesian Rupiahs.
Not all segments of Darya-Varia Laboratoria Tbk PT experienced an increase in sales in 2017:
sales of Toll Manufacturing fell 8.4% to 292.43 billion Indonesian Rupiahs.